Clinical Trials Update: Sept. 22, 2006
Claudication Generalized Anxiety Disorder (GAD) Clostridium Difficile-Associated Diarrhea
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This study will evaluate an investigational medication to treat intermittent claudication. Volunteers 40-80 with a history of intermittent claudication of the legs for six months with no change in symptoms in the prior three months may be included. The primary symptom is pain in one or both legs while walking, primarily affecting the calves, that does not go away with continued walking and is relieved by rest. Compensation for time and travel may be provided.
The research site is in St. Louis, Mo.
Generalized Anxiety Disorder (GAD)
This study seeks participants to evaluate an investigational treatment for generalized anxiety disorder (GAD). Symptoms of GAD may include excessive worry, anxiety, restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbance. Candidates 18-65 may qualify.
The research site is in San Diego, Calif.
Clostridium Difficile-Associated Diarrhea
This study will compare a 10-day course of rifaximin versus vancomycin to treat clostridium difficile-associated diarrhea (CDAD). Men and women 18 older with acute diarrhea and at least one other sign of enteric infection -- such as fever, nausea/loss of appetite, vomiting, severe abdominal pain or discomfort -- may be eligible. People who have had a previous episode of clinically diagnosed clostridium difficile within the past six months, or a chronic disease associated with diarrhea (i.e., inflammatory bowel disease) will not be eligible for this study.
The research site is in Brooklyn Center, Minn.
Copyright 2006 Thomson CenterWatch. All rights reserved.